

Special Issue

Imaging and Liquid Biopsy Biomarkers for Cancer Diagnosis and Treatment

Message from the Guest Editors

Biomarkers are essential for cancer diagnosis and treatment. Imaging and liquid biopsy are both noninvasive methods that can be used to extract quantitative biomarkers repeatedly. A liquid biopsy involves testing blood and other bodily fluids. Radiomics and machine learning (ML)/ deep learning (DL) methods have been developed to study tumor heterogeneity. Imaging focuses on the tumor extent and heterogeneity measurement, while liquid biopsy detects tumor-derived molecules in circulation. In this Special Issue, we are interested in manuscripts that report work combining both imaging and liquid biopsy to diagnosis or treat cancer. Imaging modalities include magnetic resonance imaging (MRI), X-Ray imaging, computed tomography (CT), ultrasound, and nuclear medicine scans. The liquid biopsy includes tests that can evaluate circulating tumor cells (CTC), disseminated tumor cells (DTC), and circulating tumor DNA or RNA (ctDNA, ctRNA). We welcome original research articles or comprehensive review articles focusing on the combination of quantitative imaging and liquid biopsy biomarkers for cancer detection, staging, prognosis, or monitoring treatment response.

Guest Editors

Dr. Wen Li

Department of Radiology and Biomedical Imaging, University of California, 550 16th Street, San Francisco, CA 94158, USA

Dr. Mark Jesus M. Magbanua

Department of Laboratory Medicine, University of California, 2340 Sutter Street, San Francisco, CA 94115, USA

Deadline for manuscript submissions

closed (31 August 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/167308

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)